Product Center
Announcement of Pre increase in Performance for 2025 Released
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-02-26
- Views:
(Summary description)Today,Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio", stock code: 02627. HK), based on a preliminary review of the company's unaudited major financial data during the reporting period, issued a pre increase announcement for the year 2025.
Announcement of Pre increase in Performance for 2025 Released
(Summary description)Today,Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio", stock code: 02627. HK), based on a preliminary review of the company's unaudited major financial data during the reporting period, issued a pre increase announcement for the year 2025.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-02-26 09:12
- Views:
Today,Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio", stock code: 02627. HK), based on a preliminary review of the company's unaudited major financial data during the reporting period, issued a pre increase announcement for the year 2025.
According to preliminary calculations by the company's finance department, it is expected to achieve operating revenue of approximately RMB 44.6 million to RMB 493 million in 2025, an increase of approximately 71.8% to 89.9% year-on-year.
The company adheres to a differentiation strategy, continuously invests in research and development expenses, and deeply cultivates the subunit influenza vaccine market. Both the trivalent and quadrivalent influenza virus subunit vaccines have gradually become the first and only full dose subunit influenza vaccines for the entire population in China. At the same time, the company continuously strengthens its quality management system governance capabilities, empowers intelligent manufacturing and intelligent supervision through information systems and means, ensures stable product production quality, maintains a 100% pass rate for batch issuance, and continuously improves operational efficiency, becoming an important cornerstone for the company's rapid revenue growth.
Thanks to the company's precise marketing strategy, a "digital+academic" dual wheel driven marketing model has been established. Utilizing big data models to achieve real-time visualization analysis of sales data, accurately dividing target blocks, conducting sand table deduction and strategy correction, and formulating precise and agile differentiated policies. Compared to 2024, product shipments in 2025 will further increase coverage to 232 disease control centers and 2563 vaccination clinics, providing consumers with a wider range of regional choices; At the same time, the company continues to conduct large-scale post listing evaluations and conducts in-depth academic research on special populations such as pregnant women and patients with nephrotic syndrome. From provincial and urban areas to end markets, academic promotion services have achieved comprehensive coverage, truly reaching end consumers. In addition, relevant departments such as the government continue to carry out popular science education on influenza vaccines, and residents' awareness of influenza vaccination has significantly increased. Driven by multiple favorable factors, the company's operating revenue has achieved rapid growth, its commercial operation capability and comprehensive industrial layout have continued to improve, and industrialization development has steadily advanced.
In addition, based on continuous investment in research and development, the company has achieved initial results in cost reduction and efficiency improvement. Despite a significant increase in expenses related to the initial public offering, the company's net loss has further narrowed compared to the same period last year.
Explanation:
The above information is only a preliminary assessment made by the management of our company based on the unaudited comprehensive management accounts of our group as of 2025. The above information has not been audited or reviewed by our company's auditors and may be subject to adjustments and changes. The financial performance and performance details of our group as of the fiscal year 2025 will be disclosed in our annual performance announcement, which is expected to be published by the end of March 2026.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
